Sanofi SA (NASDAQ:SNY) on Tuesday reported Phase 2 data for its experimental therapy lunsekimig in chronic respiratory diseases, highlighting meaningful improvements in asthma and nasal polyp patients, while showing mixed outcomes in a separate skin disorder study.

Strong Outcomes In Asthma Study

In the Phase 2b AIRCULES trial, lunsekimig met both its primary and key secondary endpoints, demonstrating statistically significant reductions in exacerbations and improved lung function.

The trial assessed lung performance using pre-bronchodilator forced expiratory volume (FEV1).

The study included adults with moderate-to-severe asthma, a population characterized by persistent symptoms and frequent flare-ups despite standard treatments.

The results suggest the drug may address underlying inflammatory pathways driving disease severity.

Positive Results In Nasal Polyp Study

Sanofi also reported encouraging findings from the Phase 2a DUET study in chronic rhinosinusitis with nasal polyps.

Lunsekimig achieved its primary endpoint, showing a reduction in nasal polyp size.

Key secondary measures also improved, including nasal congestion scores and imaging-based assessments using the Lund-Mackay CT scale at Week 24, reinforcing the therapy's potential